One Million Solutions in Health™ Announces a Signature Square™ Event for a Unique Tumor-Associated Antigen for Cancer Vaccine

A scientist from the National Institute on Aging, National Institutes of Health, will be making a first-ever presentation about a unique tumor-associated antigen for cancer vaccines via the One Million Solutions in Health Signature Square™ program which brings together Subject Matter Experts to evaluate new or established scientific technology.

One Million Solutions in Health™ is pleased to announce another presentation in its ongoing effort to help effect and drive the NIH research Road Map, and find more collaborations and licensing deals for the NIH via  the Signature Square™ program. This particular opportunity features an exceptional discovery in the search for unique cancer antigens that can potentially create cancer vaccines.

One Million Solutions in Health™ has established a one-of-a-kind, new partnership with the United States’ National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) to increase awareness and understanding of NIH technologies by potential partners in the life science and healthcare industries.

The Signature Square™ program brings together Subject Matter Experts to evaluate new or established scientific technology. The Signature Square™ program provides feedback to commercial providers, academics and public sector scientists on technology in the healthcare or life science industry. The vendor or scientist discusses their solution during a live webinar presentation with an audience of relevant Subject Matter Experts.  This particular opportunity features a NIH scientist who has isolated a tumor-associated antigen (TAA) that is widely expressed in various human tumors. This can set the stage for a cancer vaccine solution.

The Signature Square™ evaluation is based on several criteria that summarize a new or established technology’s Market Readiness and Value Proposition to the Marketplace. The final outcome of each evaluation results in a ranking: Blockbuster, Upstart, Novel or Innovator. This is an opportunity for technology providers to receive direct evaluation, which can be used to inform potential investors and partners.

“The Signature Square program with this scientist will be presenting some outstanding results. Understanding how immune cells control diseases like cancer, and how we can use this knowledge to develop potent therapeutic formulations to combat cancer, with a patented solution that is ready to be licensed, is one of the most important pieces of our work,” says Dawn Van Dam, President and CEO of One Million Solutions in Health. “Because this technology has such major applications, it was important to present it to a diverse audience. In this way, he can better direct the Road Map for this technology based on the feedback of the Subject Matter Experts from various backgrounds.”

Current thinking suggests the need to induce immune responses against cancer. In considering a cancer vaccine, in order to be effective, it needs to have a unique target, against which immune cells will be responding. This technology, which has found a unique tumor-associated antigen for cancer vaccines, has the potential to elicit long-lasting, disease-free survival.

For those interested in attending this event, please click on the link here: http://www.onemillionsolutionsinhealth.org/event/tumor-associated-antigen/.

To know more about the Signature Square™ program, please contact Dawn Van Dam, President of One Million Solutions in Health.

Alternatively, if you would like to see the details of the all of the NIH Signature Square™ events, along with their full reports and recordings of the Signature Square™ presentations, please contact us for more details on how individuals or companies can join the Technology Evaluation Consortium™ and have full access to all of the Signature Square™ evaluations.

ABOUT ONE MILLION SOLUTIONS IN HEALTH

The goal of One Million Solutions in Health is to shape health care by sharing solutions and, importantly, to accelerate the discovery, development and delivery … of innovative cures, treatments and preventative measures for patients around the world.

In this next year, we will be reviewing 1000’s of new solutions and new scientific discoveries. By engaging scientists, entrepreneurs, investors, innovators, industry experts, health care professionals, and patients across various disciplines, and from around the world, we can utilize the power of the internet to disrupt things in a positive and transformative way to accelerate the movement of new solutions and scientific discoveries from the scientist to the patient.

We are on our way towards accelerating high-potential innovations, catalyzing investment and increasing awareness of, and support for, transformative ideas to improve health and save lives. By facilitating efforts to ensure organizations can Connect, Learn + Share, Innovate and Collaborate, our vision is to improve health care delivery, accelerate life sciences research and share patient and consumer-focused ideas and solutions.

As a not-for-profit, we welcome your participation and are thrilled to have you be a part of this transformative journey!

ABOUT THE TECHNOLOGY EVALUATION CONSORTIUM 

The Technology Evaluation Consortium™ from One Million Solutions in Health™ is dedicated to improving and accelerating life sciences R&D and health care outcomes. The Technology Evaluation Consortium brings together life sciences and/or health care companies and industry vendors or scientists, and other relevant partners (e.g., government and Universities), to evaluate and validate technologies or services in a collaborative environment.

The model empowers technology providers/scientists and industry end-users to collectively assess a number of solutions in a cost-effective manner, producing a depth and breadth of results that no company can achieve alone. Our mission is to triage and streamline new technology consideration for the industry and to be the place for the industry to conduct their evaluations and validations.